Brief: Xbrane: U.S. FDA Filing Acceptance For Lucentis (Ranibizumab) Biosimilar Candidate

Xbrane Biopharma AB

21/06/2023 11:15

June 21 (Reuters) - Xbrane Biopharma AB  XBRANE.ST :
    * XBRANE ANNOUNCE U.S. FDA FILING ACCEPTANCE FOR A LUCENTIS®
(RANIBIZUMAB) BIOSIMILAR CANDIDATE
    * REGULATORY PROCESS CAN BE INITIATED WITH A BIOSIMILAR USER
FEE
AMENDMENT GOAL DATE OF APRIL 21ST, 2024

Source text for Eikon:  ID:nMFN4MmDpg 
Further company coverage:  XBRANE.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))